Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.79 |
| ▸ | TSHR | P16473 | 2/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.79 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.79 |
| ▸ | THRB | P10828 | 2/20 | 0.78 |
| ▸ | MAPT | P10636 | 3/20 | 0.73 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26687678 | 0.89 | CYP1A2 (0.81) | TP53CYP1A2CYP3A4CYP2C9TSHR | |
| SCHEMBL26689337 | 0.89 | TP53 (0.82) | TP53CYP1A2CYP3A4CYP2C9TSHR | |
| SCHEMBL26689829 | 0.89 | TP53 (0.82) | TP53CYP1A2CYP3A4CYP2C9TSHR | |
| SCHEMBL24045329 | 0.88 | TP53 (0.81) | TP53THRBMAPTLMNA | |
| SCHEMBL24045351 | 0.82 | MAPT (0.70) | TP53CYP1A2CYP3A4CYP2C9TSHR | |
| SCHEMBL24045352 | 0.79 | MAPT (0.83) | TP53THRBMAPTLMNA | |
| SCHEMBL10424919 | 0.79 | TSHR (0.71) | TP53CYP1A2CYP3A4CYP2C9TSHR | |
| SCHEMBL24045258 | 0.79 | MAPT (0.89) | TP53CYP1A2CYP3A4CYP2C9TSHR | |
| SCHEMBL24045326 | 0.78 | MAPT (0.87) | TP53CYP1A2CYP3A4CYP2C9TSHR | |
| SCHEMBL24045330 | 0.77 | MAPT (1.00) | TP53THRBMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339878-A1 | SLC26A3 INHIBITORS AND USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-26 | — | — | US | disclosed |
| US-20230339878-A1 | SLC26A3 INHIBITORS AND USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-26 | — | — | US | disclosed |
| US-11591304-B2 | SLC26A3 inhibitors and use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-02-28 | — | — | US | disclosed |
| US-20210363123-A1 | SLC26A3 INHIBITORS AND USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339878-A1 | SLC26A3 INHIBITORS AND USE THEREOF | SLC26A3, SLC10A2, SLC10A6 | TP53 3893/4885CYP1A2 1852/4885CYP3A4 1722/4885 |
| US-20210363123-A1 | SLC26A3 INHIBITORS AND USE THEREOF | SLC26A3, SLC10A2, SLC10A6 | TP53 4024/4885CYP1A2 1718/4885CYP3A4 1464/4885 |
| US-11591304-B2 | SLC26A3 inhibitors and use thereof | SLC26A3, SLC10A2, SLC10A6 | TP53 4024/4885CYP1A2 1718/4885CYP3A4 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.